Verification register Bio, Health & Neuro
Current reading
Readiness band and full integer triple
AI-assisted assembly · derived results
Readiness band
Ready
Primary summary from verified readiness
- Confidence
- 85% · stale
- Computed at
- 2026-09-30T21:38:13.012866+00:00
- Claimed
- 60
- Reported
- 55
- Verified
- 55
- Gap
- +5
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed leads verified
Evidence strength Strong
Decision
What the current evidence supports
Agent-assisted assessment · independently reviewed · 2026-09-30
Consider Orzeyful for adult NT1 within specialist-led care once local access is available.
- Why
- Controlled trials and FDA review support clinical benefit, while long-term safety and routine-care experience remain limited.
- Next
- Confirm availability and the approved prescribing information, and review interactions, tolerability and alternatives with a sleep specialist.
Constraints
Blockers
- U.S. availability depends on completion of DEA scheduling and launch arrangements.
- Common insomnia and urinary effects can affect tolerability.
- Strong CYP3A inhibitors are contraindicated.
- Long-term safety, durability and direct comparisons with established treatments remain limited.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 12
- Tier 1
- 9
- Tier 2
- 3
- Tier 3
- 0
- Supports
- 7
- Contradicts
- 4
- Context
- 1
- Latest observed
- 2026-08-05
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Revision 3
- 2026-08-10 Reading moved from ready to ready.
- 2026-09-22 Reading moved from ready to ready.
- 2026-09-30 Reading moved from ready to ready.